John Hunter, MD
Colon & Rectal Surgery · Mobile, ALNPI 1780845040
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.1%), travel and lodging and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Intuitive Surgical at 53.5% of the total. Reporting peaked in 2022 at $18,648 and has fallen 92.8% since, to $1,345 in 2025.
Across 117 payments — averaging $284.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$18K
- Ambu Innovation GmbH$14K
- Medtronic$443
- Baxter Healthcare$297
- Ambu Inc.$276
- Trevena, Inc.$162
- plus $629 from 11 others
What the payments were for
- Consulting fees$13,69241%
- Travel & lodging$7,97724%
- Food & beverage$4,82114%
- Education$6,82920%
- Gifts$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 81 | $17,828 |
| Ambu Innovation GmbH | 1 | $13,692 |
| Medtronic | 8 | $443 |
| Baxter Healthcare | 4 | $297 |
| Ambu Inc. | 4 | $276 |
| Trevena, Inc. | 6 | $162 |
| Virtual Incision Corporation | 1 | $154 |
| Axonics, Inc. | 1 | $120 |
| Myriad Genetic Laboratories, Inc. | 1 | $119 |
| Histosonics, Inc. | 1 | $71 |
| Merck | 3 | $45 |
| Smith+Nephew | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| TELA Bio, Inc. | 1 | $19 |
| Pacira Pharmaceuticals Incorporated | 1 | $18 |
| Acell, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few colon & rectal surgery providers in Alabamato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $965 |
| Methocarbamol | 11 | $564 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 25 | $149 |
| Neomycin Sulfate | 20 | $123 |
| Metronidazole | 23 | $81 |
| Diazepam | 20 | $59 |
Paid to pharmacies, not to this prescriber.
Other colon & rectal surgery in Mobile
- Isaac PayneMobile$163K
- Paul RiderMobile$37K
- Leander GrimmMobile$1K
- Gregory KennedyBirmingham$21K
- Andrew MitchellHuntsville$8K
- Rachel SaboBirmingham$8K
- Javad GolzarianHuntsville$8K
- Jon RosserBirmingham$8K
- Stephen ClarkHuntsville$8K
- Mark ParkerBirmingham$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.